News
The injectable production specialist has snapped up a 65-acre property with more than 300,000 square feet of usable space to ...
The importance of a homegrown biomanufacturing workforce to North Carolina’s swiftly growing life sciences industry was a consistent theme during a recent press tour of the state attended by Fierce | ...
A recently launched video series from the Biotechnology Innovation Organization (BIO) seeks to show how biotech may be able ...
After purging the CDC’s vaccine advisory committee and replacing it with his own appointments, U.S. Health Secretary Robert F ...
In its own communique issued shortly after the FDA’s, Sarepta elaborated on the situation and confirmed a Roche statement to ...
After what Bavarian Nordic described as “intense negotiations,” the Danish vaccines maker has agreed to be acquired by a ...
A new campaign invites people to chew over the idea of becoming stem cell donors—literally. | A new campaign invites people ...
On Nov. 26, 2019, ChemoCentryx issued a press release announcing that the Advocate trial met both of its primary endpoints, saying Tavneos showed noninferiority of disease remission at 26 weeks and ...
Sun Pharmaceutical and its Taro Pharmaceutical subsidiary are washing their hands of another segment of a years-long ...
Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs-down, Europe’s Committee for Medicinal Products for Human Use (CHMP) has ...
GSK is taking to the airwaves to get the message out about respiratory syncytial virus (RSV), presenting a TV special about how the pathogen has affected athletes in the upcoming National Senior Games ...
Despite a new setback for Elevidys in Europe, Roche—which markets Sarepta’s gene therapy outside the U.S.—remains committed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results